Kotak MF Buys Emcure Stake: ₹612-Cr Deal in 2026

Key moves that put pharma stocks in focus

Kotak Mahindra Mutual Fund (Kotak MF) was at the centre of two sizeable secondary transactions in listed pharmaceutical companies, buying shares in Emcure Pharmaceuticals and Ajanta Pharma. The transactions were disclosed through exchange block and market deal data and came at a time when institutional flows into large, liquid pharma names have remained active.

In Emcure, the seller was BC Investments IV, a Bain Capital-owned investment holding entity. In Ajanta, the seller was a promoter entity, Ravi Agrawal Trust. Both stocks ended higher on the day, even as the transactions were executed at pre-agreed prices typical of large institutional trades.

Emcure block deal: Kotak MF buys 36 lakh shares

Kotak MF acquired 36 lakh shares of Emcure Pharmaceuticals, representing a 1.89% equity stake, via open market transactions dated June 9. The shares were bought from BC Investments IV at a transaction price of ₹1,700 per share. The deal value was ₹612 crore.

On the National Stock Exchange (NSE), Emcure Pharmaceuticals shares rose 1.5% to ₹1,744.6. The stock was reported to be trading above key moving averages.

The block deal price of ₹1,700 per share was described as a discount to the prevailing market price, which is a common feature in large institutional transactions designed to facilitate bulk stake sales.

Who sold: Bain Capital affiliate BC Investments IV

BC Investments IV was the counterparty in the Emcure transaction. As of March 2026, BC Investments IV held a 3.87% stake in Emcure Pharmaceuticals. Following the June 9 sale of 1.89%, the Bain-linked entity’s stake position would reduce relative to that March level, based on the disclosed numbers.

Separate exchange data in the provided information also shows another Bain-linked sale in Emcure: BC Investments IV offloaded 18 lakh shares, or a 0.95% stake, at an average price of ₹1,608.20 per share for ₹289.47 crore. After that transaction, BC Investments IV’s holding declined to 2.93% from 3.87%.

Another institutional buyer: Norway’s sovereign wealth fund

In the 0.95% transaction involving 18 lakh shares, Norway’s Government Pension Fund Global was disclosed as the buyer at the same average price of ₹1,608.20 per share. This highlights that Emcure’s traded liquidity can absorb sizable blocks when global long-only institutions and domestic mutual funds are active on the buy side.

The information provided also notes that Bain Capital had sold a 2.4% stake in Emcure in July 2025 for ₹563 crore, indicating a multi-step reduction over time through market-based exits.

Ajanta Pharma: promoter trust sells 2.76% stake

Activity was also seen in Ajanta Pharma, where the promoter entity Ravi Agrawal Trust sold 34.5 lakh shares, representing a 2.76% stake, for ₹1,023.96 crore. The transaction price was ₹2,968 per share.

Ajanta Pharma closed 1.63% higher at ₹3,017.2 on the NSE. The presence of large institutional buyers alongside a promoter sell-down often reduces immediate supply overhang concerns, though the longer-term interpretation depends on subsequent disclosures and holdings.

Buyers in Ajanta: Kotak MF and Aditya Birla Sun Life MF

Kotak MF and Aditya Birla Sun Life Mutual Fund (ABSL MF) were the buyers in the Ajanta Pharma deal. Kotak MF purchased an additional 21.02 lakh shares for ₹623.95 crore. ABSL MF purchased an additional 13.47 lakh shares for ₹400 crore.

The split of quantities and values aligns with the disclosed aggregate seller quantity of 34.5 lakh shares. The disclosed transaction price for the Ajanta trade was ₹2,968 per share.

What earlier reports said on Bain’s planned Emcure selldown

The provided information includes earlier media reports and term-sheet details suggesting Bain Capital, via BC Investments IV, had explored additional block sales in Emcure. One report cited a plan to sell up to 2% of Emcure at an indicative floor price of ₹1,296.51 per share, implying a 7% discount to a referenced closing price of ₹1,394.10, with a 90-day lock-in for shares sold.

Another report mentioned an expected 2.4% stake sale of about 45.5 lakh shares at a floor price of ₹1,279.80 per share for an estimated ₹551 crore, with Kotak Securities referenced as a manager in that context. These reports were positioned as market chatter pending exchange disclosures, and the article notes that final confirmation typically comes through official exchange filings.

Snapshot table: key disclosed deal terms

Market impact: what the numbers indicate

Both Emcure and Ajanta finished in the green on the NSE on the day referenced, with Emcure up 1.5% to ₹1,744.6 and Ajanta up 1.63% to ₹3,017.2. For Emcure, the ₹1,700 block price sat below the traded price, reflecting the standard trade-off in large block execution where buyers receive a modest discount for taking bulk supply in one shot.

The disclosed buyers were long-only institutions, which typically reduces uncertainty around immediate re-selling pressure. At the same time, Bain Capital’s affiliate has been a consistent seller across multiple disclosed instances, including the June 9 block, the later 0.95% offload, and the July 2025 sale of 2.4% for ₹563 crore.

Analysis: why these deals matter for investors

For Emcure, the repeated stake sales by a private equity-linked shareholder underline a gradual monetisation process that is common after public listings. The presence of large domestic mutual funds and global institutions on the buy side suggests the stock has sufficient depth to handle secondary exits without necessarily triggering sharp price dislocations, although pricing discounts can widen depending on supply.

For Ajanta, the key signal is the absorption of a promoter entity’s 2.76% stake sale by two domestic mutual funds. The disclosed trade price of ₹2,968 versus the close of ₹3,017.2 shows that the market maintained levels after the transaction, which is often watched as an indicator of demand strength on the day of a large block.

Conclusion

Kotak MF’s ₹612 crore purchase of a 1.89% stake in Emcure from Bain Capital’s affiliate, alongside its participation in Ajanta Pharma’s promoter stake sale, highlights continued institutional appetite for liquid pharma names. Further clarity on ownership changes will come from subsequent shareholding pattern updates and exchange disclosures tied to the disclosed transactions.